급성관상동맥 증후군 치료를 위한 국내 · 외 항혈소판제 약물요법 가이드라인 비교 연구
A Comparative Study the USA, Europe and Korea Guidelines of Antiplatelet Therapy for Patients with Acute Coronary Syndrome
Objective: Patients with acute coronary syndrome (ACS) are typically managed with dual antiplatelet therapy of acetylsalicylic acid (aspirin) and P2Y12 receptor inhibitor. In this study, we discussed current and previous antiplatelet therapy guidelines and compared with guidelines of the USA (ACC/AHA), Europe (ESC) and Korea (KSC). Method: This study investigated from ACC/AHA Joint Guidelines (the USA), ESC Clinical Practice Guidelines (Europe) and Korea Society of Interventional Cardiology (Korea) web site, respectively. Results: It is significant that difference between the current and the previous guidelines was integration of terminology from clopidogrel to P2Y12 receptor inhibitors since prasugrel and ticagrelor, new antiplatelet drugs, has been added. The other difference was all three guidelines has differences in dose of aspirin. The most notable difference was class of recommendation (COR) in P2Y12 receptor inhibitors. ACC/AHA and Korean guidelines recommend clopidogrel, prasugrel, and ticagrelor with COR IB; whereas, ESC recommend prasugrel and ticagrelor with IB which is higher than clopidogrel with IC. Conclusion: This research addresses important movement to revise the Korean existing guideline recommendations. New Korean antiplatelet therapy guideline should be avoiding obvious differences in ACC/AHA and ESC guidelines and harmonizing international guidelines.
목차
ABSTRACT 연구 방법 연구 결과 미국과 유럽의 급성 관상동맥 증후군 치료에서 약물요법가이드라인 현황 미국 ACC/AHA 가이드라인 2009년도와 2013년도 비교 : ST분절 상승 심근경색증 미국 ACC/AHA 가이드라인 2011년도와 2012년도 비교 : 불안정 협심증/ST분절 비상승 미국, 유럽 그리고 한국의 급성 관상동맥 증후군 치료에서항혈소판 약물요법 가이드라인 비교 : ST분절 상승 심근경색증 미국, 유럽 그리고 한국의 급성 관상동맥 증후군 치료에서항혈소판 약물요법 가이드라인 비교: 불안정 협심증/ST분절 비상승 심근경색증 고찰 결론 참고문헌